Biotech Knockoffs Lure Novartis

Biotech Knockoffs Lure Novartis
“A big pharma player is expanding its generics business. Expect others to follow
The divide between those making brand-name drugs and those producing generics is about to become a bit less clear. “

Leave a Reply

Your email address will not be published. Required fields are marked *

Get email updates

Enter your email address to subscribe to this blog and receive notifications of new posts by email.